Sage Historical Cash Flow
| SAGE Stock | USD 5.52 0.52 10.40% |
Analysis of Sage Therapeutic cash flow over time is an excellent tool to project Sage Therapeutic future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Total Cash From Financing Activities of 5.7 M or End Period Cash Flow of 68.7 M as it is a great indicator of Sage Therapeutic ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Sage Therapeutic latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Sage Therapeutic is a good buy for the upcoming year.
Sage |
About Sage Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Sage balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Sage's non-liquid assets can be easily converted into cash.
Sage Therapeutic Cash Flow Chart
Add Fundamental
Free Cash Flow
The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.Depreciation
Depreciation indicates how much of Sage Therapeutic value has been used up. For tax purposes Sage Therapeutic can deduct the cost of the tangible assets it purchases as business expenses. However, Sage Therapeutic must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.Capital Expenditures
Capital Expenditures are funds used by Sage Therapeutic to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Sage Therapeutic operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Sage Therapeutic's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Sage Therapeutic current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sage Therapeutic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For information on how to trade Sage Stock refer to our How to Trade Sage Stock guide.At present, Sage Therapeutic's Change To Inventory is projected to increase significantly based on the last few years of reporting. The current year's Investments is expected to grow to about 515.2 M, whereas Free Cash Flow is projected to grow to (514.1 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Capital Expenditures | 372K | 937K | 553K | 525.4K | Depreciation | 4.2M | 1.1M | 1.4M | 1.3M |
Sage Therapeutic cash flow statement Correlations
Click cells to compare fundamentals
Sage Therapeutic Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Sage Therapeutic cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (64.2M) | 1.5B | (1.4B) | (131.5M) | (91.6M) | (87.1M) | |
| Free Cash Flow | (534.5M) | 663.9M | (378.6M) | (461.0M) | (541.1M) | (514.1M) | |
| Change In Working Capital | 6.7M | (39.7M) | (18.5M) | 5.7M | (67.4M) | (64.0M) | |
| Begin Period Cash Flow | 193.3M | 129.1M | 1.7B | 295.5M | 164.0M | 297.8M | |
| Other Cashflows From Financing Activities | 52.0M | 9.3M | 13.3M | 3.1M | 6.0M | 5.7M | |
| Depreciation | 2.3M | 2.6M | 4.2M | 1.1M | 1.4M | 1.3M | |
| Capital Expenditures | 5.8M | 345K | 372K | 937K | 553K | 525.4K | |
| Total Cash From Operating Activities | (528.7M) | 664.3M | (378.2M) | (460.0M) | (540.6M) | (513.6M) | |
| Net Income | (680.2M) | 606.1M | (457.9M) | (532.8M) | (541.5M) | (514.4M) | |
| Total Cash From Financing Activities | 607.6M | 426.8M | 13.3M | 3.1M | 6.0M | 5.7M | |
| End Period Cash Flow | 129.1M | 1.7B | 295.5M | 164.0M | 72.3M | 68.7M | |
| Change To Liabilities | 15.0M | (43.7M) | 6.7M | 13.1M | 11.7M | 6.1M | |
| Stock Based Compensation | 153.2M | 96.0M | 104.6M | 61.6M | 73.4M | 66.7M | |
| Other Non Cash Items | (10.6M) | (688K) | (10.6M) | 4.4M | (6.5M) | (6.1M) | |
| Sale Purchase Of Stock | (2.2M) | 9.3M | (1.4M) | (43K) | (903K) | (857.9K) | |
| Investments | (137.4M) | 443.0M | (1.0B) | 326.4M | 490.6M | 515.2M | |
| Total Cashflows From Investing Activities | (143.2M) | 442.7M | (1.0B) | 325.4M | 292.9M | 307.5M | |
| Cash And Cash Equivalents Changes | (64.2M) | 1.5B | (1.4B) | (131.5M) | (118.4M) | (112.5M) | |
| Cash Flows Other Operating | (8.4M) | 3.9M | (18.4M) | (12.2M) | (11.0M) | (10.5M) | |
| Change To Operating Activities | 25.4M | (28.2M) | (25.2M) | (2.8M) | (2.5M) | (2.4M) | |
| Other Cashflows From Investing Activities | (137.4M) | 443.0M | (1.0B) | 326.4M | 293.7M | 308.4M | |
| Change To Netincome | 149.6M | 94.3M | 94.0M | 60.1M | 69.1M | 70.3M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Sage Therapeutic is a strong investment it is important to analyze Sage Therapeutic's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Sage Therapeutic's future performance. For an informed investment choice regarding Sage Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sage Therapeutic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For information on how to trade Sage Stock refer to our How to Trade Sage Stock guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sage Therapeutic. If investors know Sage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sage Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.57) | Revenue Per Share 1.76 | Quarterly Revenue Growth 3.371 | Return On Assets (0.30) | Return On Equity (0.49) |
The market value of Sage Therapeutic is measured differently than its book value, which is the value of Sage that is recorded on the company's balance sheet. Investors also form their own opinion of Sage Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Sage Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sage Therapeutic's market value can be influenced by many factors that don't directly affect Sage Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sage Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sage Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sage Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.